# Effect of Aprotinin on Transfusion Requirements and Blood Loss in Patients Undergoing Elective Primary Total Hip Replacement

> **NCT00668031** · PHASE3 · COMPLETED · sponsor: **Bayer** · enrollment: 359 (actual)

## Conditions studied

- Blood Loss, Surgical

## Interventions

- **DRUG:** Trasylol (Aprotinin, BAYA0128)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00668031
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-02
- **Primary completion:** 2006-01
- **Final completion:** 2006-01
- **Target enrollment:** 359 (ACTUAL)
- **Last updated:** 2014-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00668031

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00668031, "Effect of Aprotinin on Transfusion Requirements and Blood Loss in Patients Undergoing Elective Primary Total Hip Replacement". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00668031. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*